Volume 4, Issue 3 (August 2025)                   Health Science Monitor 2025, 4(3): 207-211 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Asghari R, Mahmoudi-Nejad S, Vazifeshenas S, Abdi Rad I, Bagheri M. Molecular Genetic Characterization of Philadelphia Chromosome in Patients with Chronic Myeloid Leukemia in the North-West of Iran. Health Science Monitor 2025; 4 (3) :207-211
URL: http://hsm.umsu.ac.ir/article-1-233-en.html
Molecular Genetic Characterization of Philadelphia Chromosome in Patients with Chronic Myeloid Leukemia in the North-West of Iran
Rahim Asghari , Salar Mahmoudi-Nejad , Sara Vazifeshenas , Isa Abdi Rad , Morteza Bagheri *
Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran
Abstract:   (224 Views)

Background The Philadelphia (Ph) chromosome, characterized by the translocation t(9;22)(q34;q11), is found in 90–95% of individuals diagnosed with Chronic Myeloid Leukemia (CML) and in 0.1 - 3% of those with Acute Myeloid Leukemia (AML). The detection of chromosomal abnormalities plays a crucial role in the diagnosis and management of hematological disorders. The present study aimed to perform molecular genetic characterization of Ph in patients with CML in the north-west of Iran.
Methods A total of 45 new cases of adult patients with CML were studied at the Department of Internal Medicine, Imam Khomeini Hospital. The Ph chromosome was detected using simple multiplex RT-PCR methods.
Results We studied 45 patients with a mean age of 55.03 ± 21.56, including 23 (51.1%) males and 22 (48.9%) females. The frequencies of b2a2, b3a3, b3a3/b3a2, b3a2, and e1a2 transcripts were 46.71%, 24.4%, 6.67%, 2.22%, 2.22%, respectively. BCR–ABL typical transcripts were not found in the rest of our patients.
Conclusion Our findings revealed that the b2a2 transcript was the most common among CML patients, while patients carrying the b3a2 transcript demonstrated better molecular responses to standard-dose imatinib. The identification of transcript types not only supports diagnosis but also guides targeted therapy and long-term monitoring. Furthermore, emerging strategies combining TKIs with novel therapeutic agents may offer promising alternatives for resistant CML cases.

Keywords: BCR–ABL, CML, Multiplex RT-PCR, Philadelphia chromosome
Full-Text [PDF 401 kb]   (87 Downloads)    
Type of Study: Research | Subject: Health promotion and disease prevention
Received: 2025/03/18 | Accepted: 2025/05/27 | Published: 2025/08/19
References
1. Juliusson G, Hough R. Leukemia. Progr Tumor Res, 43, 87-100. 2016. [DOI] [PMID]
2. Zhang L, Muscat JE, Chinchilli VM, Behura CG. Trends in Cancer Incidence and Mortality in US Adolescents and Young Adults, 2016-2021. Cancers (Basel). 2024; 16(18): 3153. [DOI] [PMID] [PMCID]
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1). [DOI] [PMID]
4. Molica M, Abruzzese E, Breccia M. Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia. Mediterr J Hematol Infect Dis. 2020; 12(1): e2020062. [DOI] [PMID] [PMCID]
5. Nekoohesh L, Ghahremani MH, Rostami S, Nikbakht M, Nekoohesh L, Naemi R, et al. A Single Center Study of Prescribing and Treatment Outcomes of Patients with Chronic Myeloid Leukemia. Int J Hematol Oncol Stem Cell Res. 2020;14(1):11-18. [DOI] [PMID] [PMCID]
6. Gondran C, Dumas P-Y, Bérard E, Bidet A, Delabesse E, Tavitian S, et al. Imatinib with intensive chemotherapy in AML with t (9; 22)(q34. 1; q11. 2)/BCR:: ABL1. A DATAML registry study. Blood Cancer J. 2024; 14(1): 91. [DOI] [PMID] [PMCID]
7. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. Arch Iran Med. 2008; 11(3): 247-251. [Google]
8. Bernt KM, Hunger SP. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol. 2014; 4: 54. [DOI] [PMID] [PMCID]
9. Seiser E, Behrens YL, Lukat S, Sembill S, Karow A, Suttorp M, Metzler M, Krumbholz M. Distribution of BCR::ABL1 Transcript Types and Response to Therapy in Pediatric Patients with Chronic Myeloid Leukemia. J Mol Diagn. 2025;27(4):282-291. [DOI] [PMID]
10. Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. Pharmaceutics. 2022;14(1):215. [DOI] [PMID] [PMCID]
11. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013. 122(6): 872-84. [DOI] [PMID] [PMCID]
12. Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leukemia Res. 2008; 32(4): 579-585. [DOI] [PMID]
13. Shi T, Huang X, Zhu L, Li X, Li L, Ye X. Adult Ph-positive acute lymphoblastic leukemia-current concepts in cytogenetic abnormalities and outcomes. Am J Cancer Res. 2020; 10(8): 2309. [Google Scholar]
14. Kaczmarska A, Śliwa P, Zawitkowska J, Lejman M. Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment. Int J Mol Sci. 2021; 22(12): 6411. [DOI] [PMID] [PMCID]
15. Zhou Q, Zhao D, Eladl E, Capo-Chichi J-M, Kim DDH, Chang H. Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia. Leukemia Res. 2023; 124: 107002. [DOI] [PMID]
16. Bagheri M, Abdi Rad I, Maleki D, Eishi A, Valizadeh N. Frequency of BCR-ABL Fusion Transcripts in Iranian Azeri Turkish patients with Chronic Myeloid Leukemia. Iranian Journal of Blood and Cancer. 2018; 10(2): 56-60. [Google Scholar]
17. Yaghmaie M, Ghaffari S, Alimoghaddam K, Ghavamzadeh A, Mousavi S, Irvani M, et al. Frequency of BCR-ABL fusion transcript in Iranian patients with chronic myeloid leukemia. Int J Hematol Oncol Stem Cell Res. 2005: 1-5. [Google Scholar]
18. Romero-Morelos P, González-Yebra AL, Herrerías-García A, Ruíz-Velázquez FA, Bueno-Rosario LJ, González-Yebra B. Distribution of BCR:: ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival. Genes. 2024; 15(5): 567. [DOI] [PMID] [PMCID]
19. Ayatollahi H, Keramati MR, Kooshyar MM, Raiszadeh M, Shakeri S, Sadeghian MH. BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran. Caspian J Intern Med. 2018; 9(1): 65. [Google Scholar]
20. Rinaldi I, Winston K. Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review. J Blood Med. 2023: 261-277. [DOI] [PMID] [PMCID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 All Rights Reserved | Health Science Monitor

Designed & Developed by : Yektaweb